Nova Eye Medical (EYE) Discussion, page-1796

@TheAnalyst007

$50 per share, that’s pretty insane to imagine. But the market caps of peers don’t lie, and 2RT treats around 3x more AMD sufferers than the anti VEGF drugs if I remember correctly? It also seems incredibly effective, a 77% reduction in progression is close enough to a cure for me, and the fee per use model means strong recurring revenue and high margins, which always attracts massive valuation multiples. The most insane thing though is that we don’t even have any real risk associated with that. iTrack Advance on its own should be able to send this to $1, 2RT is more like a massive massive massive bonus.